Safety & efficacy of sodium glucose co-transport 2 (SGLT2) inhibitors in elderly patients with heart failure. (PubMed, Front Cardiovasc Med) - Sep 5, 2026 - "Patients aged ≥65 years initiated on empagliflozin or dapagliflozin were included. However, given the single-arm retrospective design and the absence of a comparator group, these observed changes cannot be definitively attributed to SGLT2 inhibitor therapy alone and should therefore be interpreted as associations rather than evidence of a causal treatment effect. Careful clinical monitoring remains essential, particularly in patients with underlying renal impairment."
Journal • Acute Kidney Injury • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Hypoglycemia • Hypotension • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Urology
|
|
Abdullah Faiz Zaihan; Anis Nabila Mohamad; Chandini Menon Premakumar; Shairyzah Ahmad Hisham; Suharzelim Abu Bakar
|